Background: Infective thoracic aneurysms are rare and have a poor prognosis. In the past, these have been managed surgically with adjunctive antibiotic therapy. Endoluminal repair is a relatively new treatment option which may be associated with lower morbidity and mortality. Methods: The New Zealand Thoracic Aorta Stent graft registry was interrogated between December 2001 and September 2009, selecting all patients with endoluminal repair of infective thoracic aortic aneurysms. Results: Out of 184 patients on the database, four (2.2%) patients (male = 3, median age = 72) underwent endoluminal repair of an infective thoracic aortic aneurysm. The aneurysm was successfully excluded at the time of the procedure in all patients. There was a low incidence of post-procedural complications including atrial fibrillation (n= 1), pneumonia with haemoptysis (n= 1), urinary retention (n= 1) and access site seroma (n= 1). Time to discharge was mean of 26.5 days, median 22.5 days (8-53 days). One of the four patients is still alive and well at the time of reporting. Of the remaining three patients, mean survival is 486 days, median 374 days (336-748 days). Conclusions: Endoluminal repair is a treatment option for infective thoracic aneurysms, but the durability is unknown. Due to the rareness of the condition, a randomized clinical trial is unlikely to succeed. National registries such as the New Zealand Thoracic Aortic Stent provide useful information regarding this.